by The global fluorescent in situ hybridization probe market was estimated at USD 0.87 billion in 2022 and it is expected to surpass around USD 1.82 billion by 2032, poised to grow at a CAGR of 7.65% from 2023 to 2032. The fluorescent in situ hybridization probe market in the United States was accounted for USD 332.7 million in 2022.
Key Pointers
- North America region dominated the market with the largest market share of 45% in 2022.
- By Technology, the FLOW-FISH segment held the maximum revenue share of 36% in 2022.
- By Type, the DNA segment registered the registered market share of 59% in 2022.
- By Type, the RNA probes segment is anticipated to register the fastest growth rate over the forecast period.
- By Application, the cancer diagnostics segment captured the maximum market share of 44% in 2022.
- By End-Use, the clinical use segment led the market with a revenue share of 42% in 2022.
Fluorescent in situ hybridization (FISH) probes have become instrumental in the realm of molecular biology, revolutionizing the way researchers and clinicians explore the intricacies of the genome. This overview provides a comprehensive insight into the key facets shaping the fluorescent in situ hybridization probe market.
Market Growth
The growth of the fluorescent in situ hybridization probe market is propelled by several key factors. Firstly, the increasing demand for comprehensive genomic analysis in both research and clinical applications has significantly contributed to the market’s expansion. The versatility of fluorescent in situ hybridization (FISH) probes allows for precise mapping of genetic elements, addressing the growing need for detailed genomic information. Secondly, the expanding applications of FISH probes in diagnostics, particularly in the identification of genetic disorders and various types of cancers, have positioned them as integral tools in routine clinical practices.
Get a Sample: https://www.visionresearchreports.com/report/sample/40944
Report Scope of the Fluorescent In Situ Hybridization Probe Market
| Report Coverage | Details |
| Market Revenue by 2032 | USD 1.82 billion |
| Growth Rate from 2023 to 2032 | CAGR of 7.65% |
| Revenue Share of North America in 2022 | 45% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Read More: https://www.heathcareinsights.com/critical-care-diagnostics-market/
Market Dynamics
Drivers
Rising Demand for Genomic Analysis:
The fluorescent in situ hybridization probe market is driven by an escalating demand for in-depth genomic analysis in both research and clinical settings. FISH probes, with their ability to precisely target and visualize specific nucleic acid sequences, cater to the growing need for comprehensive genetic information.
Expanding Applications in Diagnostics:
FISH probes play a pivotal role in diagnostics, particularly in the identification and characterization of genetic disorders and various types of cancers. This expanding application has propelled the integration of FISH probes into routine clinical practices, driving market growth.
Restraints
Standardization Challenges:
A significant restraint facing the fluorescent in situ hybridization probe market is the lack of standardized protocols. The absence of universally accepted procedures hampers the reproducibility and comparability of FISH results across different laboratories, posing a challenge for widespread adoption and consistent interpretation of findings.
Technological Learning Curve:
While technological advancements drive market growth, the learning curve associated with adopting new technologies can act as a restraint. Training personnel on the use of advanced FISH technologies and maintaining proficiency in evolving techniques may pose challenges for laboratories and healthcare institutions.
Opportunities
Advancements in Automation:
The ongoing advancements in automation technologies present a significant opportunity for the fluorescent in situ hybridization probe market. Automation can streamline and standardize FISH procedures, reducing processing times and enhancing efficiency, thereby increasing the scalability and accessibility of these assays.
Integration with Next-Generation Sequencing (NGS):
The integration of FISH probes with Next-Generation Sequencing (NGS) technologies presents a promising opportunity. Combining the strengths of FISH for targeted analysis with the comprehensive genomic information provided by NGS can enhance the depth and breadth of genetic insights, opening new frontiers in genomic research and diagnostics.
Technology Insights
The FLOW-FISH segment held the largest revenue share of 36% in 2022 and is anticipated to grow at the fastest growth rate over the forecast period. This is owing to the growing demand for genomic profiling by healthcare professionals. Flow FISH testing can automatically screen over 10,000 cells in around 10 minutes. This approach, in addition to improving testing efficiency and standardization, achieves greater repeatability than traditional manual FISH testing by measuring 20 to 100 times more cells.
This is particularly important in fields, such as cancer research and immunology. The rising prevalence of chromosomal disorders is propelling the need for the product in the market. The technique is constantly being adopted for the diagnosis of Dyskeratosis congenita, the first inheritable disorder that is associated with the impaired maintenance of telomere. It is a rare condition that generally shows high prevalence in patients with bone marrow failure.
Type Insights
The DNA segment contributed the largest market share of 59% in 2022 due to the rising demand for molecular profiling by healthcare professionals and the presence of molecular pathology tools that are technologically advanced and help in disease stratification and prognosis for appropriate treatment. The development of technologically advanced diagnostics tools is enabling the adoption of DNA probes in the market. For instance, in July 2023, KromaTiD announced the development of over 300 telomere, centromere, and gene probes for use in directional Genomic Hybridization (dGH) in-site DNA assays. The availability of a catalog of centromere and telomere probes empowers researchers and cytogenetic cores within the academic sphere to adopt these potent and advanced assays within their own facilities, all while maintaining cost-effectiveness.
The RNA probes segment is anticipated to register the fastest growth rate over the forecast period owing to the rising use of RNA probes for cancer analysis and the ability of RNA probes to differentiate between cancer subtypes. Novel probes targeting disease-specific RNA are being developed by companies, such as the Stellaris RNA probe by BioSearch technologies and the RNAscope series by Advanced Cell Diagnostics for infectious diseases and cancer.
Application Insights
The cancer diagnostics segment generated the maximum market share of 44% in 2022. FISH probes are most commonly used in research for genetic diseases and cancer diagnostics. Increasing cancer incidences across the globe, which lead to the rising demand for sensitive, rapid, and accurate molecular diagnostic tests, are propelling the market growth. In cancer diagnostics, these probes are widely used for the diagnosis of breast and lung cancer. The development of novel diagnostics using FISH technology is further driving market growth. For instance, the UroVysion FISH test kit is used for the diagnosis of urological cancers.
On the other hand, owing to its advantages of exceptional detection precision, heightened sensitivity, and robust experimental duration, the utilization of FISH technology coupled with a fluorescent microscope has progressively enhanced the preference of these probes in cytogenetic analysis. FISH demonstrates remarkable efficacy in identifying anomalies within the MET (hepatocyte growth receptor factor) gene in non-small cell lung cancer as well as in detecting genes related to breast cancer. These factors aided by the high sensitivity and efficient testing capabilities associated with FISH probes are anticipated to drive the growth of the cancer diagnostics application segment.
End-use Insights
The clinical use segment dominated the market with a revenue share of 42% in 2022 due to the wide application of FISH probes in the detection and diagnosis of genetic disorders, cancer, and infectious diseases. Fluorescence in situ hybridization is a commonly adopted technology used for the diagnosis of genetic abnormalities. They are commonly used in clinical procedures, companion diagnostics, and research studies. The specificity & high sensitivity of this technology and the rapid assays performing speed have made this technique an important cytogenetic test that offers significant benefits in research and diagnostic studies of hematological malignancies and solid tumors.
These probes are used in research studies for gene mapping, genetic aberrations, and the identification of novel oncogenes in cancer detection and treatment. It is also used in molecular-based testing for gene mapping and identification of novel oncogenes. The clinical and microbiological detection approaches have been greatly influenced by FISH, largely attributed to its high specificity and efficiency. This makes the technology one of the most commonly adopted techniques for clinical microbiological detection.
Regional Insights
North America accounted for the largest revenue share of 45% in 2022. The dominance of the region is attributed to the rising prevalence of genetic disorders leading to birth defects, developmental disabilities, and other metabolic syndromes. According to the CDC, in 2022, around 3-4% of newborns in the U.S. were born with some form of genetic abnormality, accounting for hospitalization of approximately 10% of adults and 30% of children. FISH is estimated to provide 98% accuracy in the detection of chromosomal aberrations leading to genetic abnormalities, which further propels the growth of the market in the region.
Moreover, usage of these assays in various disease areas, such as cancer and genetic disorders, is increasing and is further anticipated to drive the demand. Favorable healthcare reimbursement policies and government reforms are anticipated to fuel market growth. Asia Pacific is anticipated to register the fastest growth rate over the coming years on account of the presence of supportive government initiatives pertaining to the increasing investments by the government and key manufacturers in the biotechnology sector posing high untapped opportunities the for development of novel diagnostics in the region.
Key Companies
- Thermo Fisher Scientific Inc.
- Perkinelmer Inc.
- BioDot
- Horizon Diagnostics
- Agilent Technologies, Inc.
- Abnova Corporation
- LGC Biosearch Technologies
- Genemed Biotechnologies, Inc.
- Oxford Gene Technology IP Limited
- Biocare Medical, LLC.
- QIAGEN (Exiqon A/S)
- GSP Research Institute, Inc.
Fluorescent In Situ Hybridization Probe Market Report Segmentations:
By Technology
- Flow FISH
- Q FISH
- Other FISH
By Type
- DNA
- RNA
- mRNA
- miRNA
- Other
By Application
- Cancer Research
- Lung
- Breast
- Bladder
- Hematological
- Gastric
- Prostrate
- Cervical
- Other
- Genetic Diseases
- Other
By End-Use
- Research
- Clinical
- Companion diagnostics
By Regional
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/40944
You can place an order or ask any questions, please feel free to contact sales@visionresearchreports.com| +1 650-460-3308
